3/14/2008
biolitec has entered into a non-binding letter of intent for the acquisition of specified assets of Diomed Holdings, Inc.
Read More |
| |
3/11/2008
biolitec 1470nm Laser Cleared for Vein Surgery
Read More |
| |
2/28/2008
David S. Turk, MD, Wins 2007 Thirlby Award for In-Office Laser Vaporization of Prostate
Read More |
| |
9/28/2007
Sales of biolitec AG increase to more than Euro 39 million – Aesthetic therapies and ambulant urology laser are growth drivers – 0.56 Euro earnings per share at June 30, 2007.
Read More |
| |
7/3/2007
US Rental Company for medical lasers places order with biolitec amounting to US $ 9.5 million for urology laser LIFE and accessories for ambulant treatment of the benign prostate hyperplasia (BPH) – reference centres for BPH treatment started in Germany according to the US model
Read More |
| |
6/27/2007
biolitec develops patented laser application for the reopening of the lacrimal duct – considerable demand for the treatment of DCR (Dacryocystorhinostomy) in Japan, the second largest health care market in the world – biolitec also sees increasing demand in India as well as in the Middle East
Read More |
| |
6/21/2007
For the first time researchers of the biolitec AG successfully managed to reduce visceral fat in an animal model - visceral fat adsorbs in the abdominal cavity by surrounding the viscera (ab-dominal fat tissue) and is inter alia responsible for metabolic risk factors such as e.g. diabetes, apoplexy as well as further cardiovascular diseases
Read More |
| |
5/31/2007
Highest earnings further on in the business fields disposables and aesthetics - Strong demand for urology lasers in the USA – Accelerating positive business development
Read More |
| |
5/25/2007
Jena, May 25, 2007 – biolitec achieved great success with its laser for the treatment of benign prostate hyperplasia (BPH) on this year’s annual meeting of the American Urological Association (AUA) in Anaheim, California.
Read More |
| |
4/27/2007
Jena, 27. April. 2007 – biolitec AG wants to significantly accelerate the launch of Foscan® in the USA. Based on the Foscan® confirmatory study biolitec requested an immediate approvability meeting with the FDA.
Read More |
| |